Pilot Study of Unrelated Cord Blood Transplantation

Myelodysplastic Syndromes Clinical Trial

Official title:

Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00916045
• Other study ID #: 07CC12
• Secondary ID: REC - 07/H0808/1
• Status: Terminated
• Phase: Phase 2
• First received: June 5, 2009
• Last updated: February 10, 2015
• Start date: September 2009
• Est. completion date: March 2012

Study information

• Verified date: March 2012
• Source: King's College Hospital NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning regimens.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

DISEASE INCLUSION CRITERIA:

In general this encompasses all haematological disorders where a volunteer unrelated donor transplant is clinically indicated.

1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option.

1. Acute myeloid leukaemia (AML) in first complete remission (CR1) with one of the following characteristics:

• High risk cytogenetic or molecular alterations (e.g. t(9;22), deletion 7/7q-, monosomy 5 or del(5q), 3q26 alterations, complex karyotype [3 or more anomalies], p53 alterations, 11q23 especially t(6;11) abnormalities, FLT-3 ITD)

• Leukocytes at diagnosis > 50 x109/l (except in cases with good prognosis molecular rearrangements for which leukocytes should be > 100 x 109/l)

2. Myelodysplastic syndromes

• International Prognosis Index (IPSS) above 1 (intermediate group 2 or high risk)

• IPSS 0 or 0.5 in the presence of cytopenias requiring treatment.

3. Therapy related AML or MDS in first CR

4. AML or MDS in second (CR2) or subsequent CR

5. Ph'-positive chronic myeloid leukaemia

i. In first chronic phase if refractory and/or intolerance to tyrosine kinase inhibitors is clearly demonstrated ii. In second chronic phase

2. Acute lymphoblastic leukaemia (ALL)

a. In CR1 with one of the following characteristics: i. Very high risk chromosome or molecular alterations (e.g. t(9;22), t(4;11), complex karyotype in adults, bcr/abl rearrangements, MLL rearrangements) ii. Slow response to induction treatment defined as the presence of >10% blasts in bone marrow at day 14 of induction treatment iii. Adults aged > 30 years iv. Adults with B ALL cell line with a number of leukocytes at diagnosis >25 x 109/L or T ALL cell line with a number of leukocytes at diagnosis >100X109/L

b. In CR2 or subsequent CR

3. Non-Hodgkin's lymphoma

1. Follicular NHL: in second or subsequent complete or partial remission

2. Mantle cell NHL: in second or subsequent complete or partial remission

3. High grade NHL: in second complete or very good partial remission

4. Hodgkin's disease

a. in second or subsequent complete or partial remission

5. Chronic lymphocytic leukaemia.

1. in second or subsequent remission

2. with adverse risk prognostic features in first remission

6. Acquired bone marrow failure syndromes

7. Other haematological malignancies for which UD bone marrow transplantation is indicated

PATIENT SELECTION

Inclusion criteria: myeloablative conditioning regimen

1. Aged under 35 years and greater than 18 years

2. Absence of HLA compatible related donor.

3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries.

4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible.

5. Availability of suitable UD-UCB unit/s.

6. Informed consent.

Exclusion criteria: myeloablative conditioning regimen

1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10 unrelated bone marrow donor

2. ECOG performance status worse than 2

3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF less than 40%.

4. Hepatic disease, with total bilirubin above 20umol/l or AST > 3 times upper limit of normal.

5. Severe hypoxaemia, pO2 < 70 mm Hg, with decreased DLCO < 70% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 60% of predicted.

6. Impaired renal function (creatinine > 2 times upper limit of normal or creatinine clearance < 50% for age, gender, weight).

7. Patients who have received previous treatment with Thymoglobulin®

8. HIV or HTLV positive patients.

9. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.

10. Life expectancy severely limited by diseases other than the disease indication for transplant

11. Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral infection

12. Serious psychiatric/ psychological disorders

13. Absence of /inability to provide informed consent

14. Serious diseases that prevent treatments with chemotherapy

15. Myelofibrosis

Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens):

1. Age under 70 years and older than 18 years

2. Absence of HLA compatible related donor.

3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries.

4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible.

5. Availability of suitable UD-UCB unit/s.

6. Informed consent.

Exclusion Criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens):

1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10 unrelated bone marrow donor

2. ECOG performance status worse than 2

3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF less than 35%.

4. Hepatic disease, with total bilirubin greater than 2 times upper limit of normal or AST > 5 times upper limit of normal.

5. Severe hypoxaemia, pO2 < 70 mm Hg, with decreased DLCO < 50% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 50% of predicted.

6. Impaired renal function (creatinine > 2 times upper limit of normal or creatinine clearance < 50% for age, gender, weight).

7. Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of total body irradiation (TBI).

8. Patients who have received previous treatment with Thymoglobulin®

9. HIV or HTLV positive patients.

10. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.

11. Life expectancy severely limited by diseases other than the disease indication for transplant

12. Serious concurrent uncontrolled infection e.g. active tuberculosis, mycoses or viral infection

13. Serious psychiatric/ psychological disorders

14. Absence of /inability to provide informed consent

15. Within 6 months of prior myeloablative transplant.

16. Patients with acute leukaemia in morphological relapse/ persistent/ progressive disease

17. Intermediate or high grade NHL, mantle cell NHL and Hodgkin's disease that is refractory or progressive on salvage therapy.

18. Myelofibrosis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Hodgkin Disease
• Leukemia
• Leukemia, Lymphoblastic, Acute
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

Intervention

Drug:
• Thiotepa

• Fludarabine

• Intravenous busulphan

• Thymoglobulin

• Ciclosporin

• Mycophenolate mofetil (MMF)

• Fludarabine

• Cyclophosphamide

Radiation:
• Radiotherapy

Drug:
• Thymoglobulin

• Ciclosporin

• Mycophenolate mofetil (MMF)

• Fludarabine

• Melphalan

• Thymoglobulin

• Ciclosporin

• Mycophenolate mofetil (MMF)

Locations

Country	Name	City	State
United Kingdom	King's College Hosptial NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
King's College Hospital NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment related mortality at day 100		Day 100	Yes
Secondary	Disease free survival at one year post-transplant for each cohort		1 year	Yes
Secondary	Chimerism		Days 14 (myeloblative conditioning only), 28, 56, 100 and months 6 and 12	No
Secondary	Incidence of neutrophil engraftment by day 42		Days 14, 28 and 42	Yes
Secondary	Incidence of platelet engraftment by 6 months		Days 14, 28, 56, 100 and month 6	Yes
Secondary	Incidence of grade II-IV and III-IV acute GVHD		Days 28, 56, 100 and months 6, 9, 12, 18 and 24	Yes
Secondary	Incidence of chronic GVHD during the first year		Day 100 and months 6 and 12	Yes
Secondary	One year overall survival for each treatment cohort		1 year	Yes
Secondary	Incidence of systemic infections		Twice a week pre-transplant to day 100 then weekly or as clinically indicated	Yes
Secondary	Incidence of CMV, adenovirus and EBV activation		Twice a week pre-transplant to day 100 then weekly or as clinically indicated	Yes
Secondary	Immune reconstitution		Days 14, 28, 56, 100 and months 6, 9, 12, 18 and 24	No
Secondary	Dynamics of EBV infection and immunity following cord blood transplantation		Days 14, 28, 56, 100 and months 6, 9 and 12	No
Secondary	The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD)		Days 14, 28, 56, 100 and months 6, 9 and 12	Yes
Secondary	Identify any possible predictive markers for patients most at risk of PTLD development		Days 14, 28, 56, 100 and months 6, 9 and 12	No
Secondary	Quality of life		Pre-transplant and months 6, 12, 18 and 24	No
Secondary	Incidence of one year relapse or disease progression for each treatment cohort		1 year	Yes